Literature DB >> 26062442

miR-181c associates with tumor relapse of high grade osteosarcoma.

Federica Mori1, Andrea Sacconi2, Valeria Canu2, Federica Ganci2, Mariangela Novello3, Vincenzo Anelli4, Renato Covello5, Virginia Ferraresi6, Paola Muti7, Roberto Biagini8, Giovanni Blandino2,7, Sabrina Strano1,7.   

Abstract

High-grade osteosarcoma (OS) is characterized by low incidence, high aggressiveness and moderate 5-years survival rate after aggressive poly-chemotherapy and surgery. Here we used miRNA profiling as a tool to possibly predict and monitor OS's development and therapeutic outcome. First, we evaluated the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) apparently evolved into an OS. We found that most of modulated miRs were associated with pathways of bone resorption and osteogenesis. miRNA expression also revealed that GCT and OS were distinct tumors. Second, we validated the observed miRNA profile in two independent casuistries of ten GCT (not evolved into malignant tumors) and sixteen OS patients. Interestingly, we found that miR-181c and other three miRNAs identified in the first step of the study were also consistently de-regulated in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate that: i) miRNAs aberrantly modulated in GCT could be predictive of its development into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic outcome.

Entities:  

Keywords:  giant cell tumor; miRNA profiling; osteosarcoma; relapse

Mesh:

Substances:

Year:  2015        PMID: 26062442      PMCID: PMC4546443          DOI: 10.18632/oncotarget.3539

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  51 in total

1.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

2.  MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell.

Authors:  Zhu Jianwei; Liu Fan; Liu Xiancheng; Bai Enzhong; Li Shuai; Li Can
Journal:  Tumour Biol       Date:  2013-06-06

3.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

4.  Malignancy in giant cell tumor.

Authors:  F Bertoni; P Bacchini; E L Staals
Journal:  Skeletal Radiol       Date:  2002-08-15       Impact factor: 2.199

5.  Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma.

Authors:  Haixia Zhang; Haotong Wu; Junheng Zheng; Pei Yu; Lixiao Xu; Pan Jiang; Jin Gao; Hua Wang; Yan Zhang
Journal:  Stem Cells       Date:  2013-03       Impact factor: 6.277

6.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

7.  Spontaneous malignant transformation of conventional giant cell tumor.

Authors:  H J Grote; M Braun; T Kalinski; N Pomjanski; W Back; U Bleyl; A Böcking; A Roessner
Journal:  Skeletal Radiol       Date:  2004-01-29       Impact factor: 2.199

8.  Using epidemiology and genomics to understand osteosarcoma etiology.

Authors:  Sharon A Savage; Lisa Mirabello
Journal:  Sarcoma       Date:  2011-03-08

9.  Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.

Authors:  Neda Mosakhani; Satu Mustjoki; Sakari Knuutila
Journal:  Mol Cytogenet       Date:  2013-07-16       Impact factor: 2.009

10.  MicroRNA-181a/b: novel biomarkers to stratify breast cancer patients for PARPi treatment.

Authors:  Federica Mori; Sabrina Strano; Giovanni Blandino
Journal:  Cell Cycle       Date:  2013-05-30       Impact factor: 4.534

View more
  10 in total

1.  MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Authors:  Valeria Canu; Andrea Sacconi; Laura Lorenzon; Francesca Biagioni; Federica Lo Sardo; Maria Grazia Diodoro; Paola Muti; Alfredo Garofalo; Sabrina Strano; Antonietta D'Errico; Gian Luca Grazi; Mario Cioce; Giovanni Blandino
Journal:  Oncotarget       Date:  2017-05-02

2.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

Review 3.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

4.  MicroRNA-181c-5p modulates phagocytosis efficiency in bone marrow-derived macrophages.

Authors:  Sarojini Singh; John Henderson; Mallikarjun Patil; Praveen K Dubey; Shubham Dubey; Ramaswamy Kannappan; Jianyi Zhang; Prasanna Krishnamurthy
Journal:  Inflamm Res       Date:  2022-01-12       Impact factor: 4.575

5.  NOVA1 acts as an oncogene in osteosarcoma.

Authors:  Chengzhen Li; Ying He; Haijing Ma; Seongho Han
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

6.  Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a.

Authors:  Zhiwen Ba; Lili Gu; Songnan Hao; Xiaofang Wang; Zhenping Cheng; Guangchen Nie
Journal:  Cell Prolif       Date:  2017-11-30       Impact factor: 6.831

7.  SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.

Authors:  Yan Ma; Jing Song; Bobin Chen; Xiaoping Xu; Guowei Lin
Journal:  Oncotarget       Date:  2016-02-09

8.  miR-628-3p regulates osteoblast differentiation by targeting RUNX2: Possible role in atrophic non-union.

Authors:  Hua Chen; Xinran Ji; Fei She; Yuan Gao; Peifu Tang
Journal:  Int J Mol Med       Date:  2016-12-28       Impact factor: 4.101

9.  Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.

Authors:  Meiyuan Chen; Min Wang; Simiao Xu; Xingjun Guo; Jianxin Jiang
Journal:  Oncotarget       Date:  2015-12-29

10.  The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma.

Authors:  Leilei Zhang; Xiaoyu He; Fang Li; Hui Pan; Xiaolin Huang; Xuyang Wen; He Zhang; Bin Li; Shengfang Ge; Xiaofang Xu; Renbing Jia; Xianqun Fan
Journal:  J Exp Clin Cancer Res       Date:  2018-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.